Adbiotech Co. Ltd.
ADBiotech Co., Ltd. develops and sells antibodies for livestock, fisheries, and humans in South Korea and internationally. The company offers antibiotic, disinfectant, helminthic, over the counter drugs, supplementary feed, and metabolic drugs. It also offers health functional and processed foods. ADBiotech Co., Ltd. was founded in 2000 and is based in Chuncheon-si, South Korea.
Adbiotech Co. Ltd. (179530) - Total Liabilities
Latest total liabilities as of September 2025: ₩27.50 Billion KRW
Based on the latest financial reports, Adbiotech Co. Ltd. (179530) has total liabilities worth ₩27.50 Billion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Adbiotech Co. Ltd. - Total Liabilities Trend (2014–2024)
This chart illustrates how Adbiotech Co. Ltd.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Adbiotech Co. Ltd. Competitors by Total Liabilities
The table below lists competitors of Adbiotech Co. Ltd. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Luzhou Xinglu Water (Group) Co., Ltd.
F:2LX
|
Germany | €4.10 Billion |
|
Nuburu Inc
PINK:BURUW
|
USA | $67.01 Million |
|
Asuransi Kresna Mitra Tbk PT
JK:ASMI
|
Indonesia | Rp1.05 Trillion |
|
Reef Casino Trust
AU:RCT
|
Australia | AU$91.42 Million |
|
Naphtha
TA:NFTA
|
Israel | ILA3.16 Billion |
|
AI/ML Innovations Inc
OTCQB:AIMLF
|
USA | $952.26K |
|
Crest Builder Holdings Bhd
KLSE:8591
|
Malaysia | RM1.03 Billion |
|
New Frontier Minerals Ltd
AU:NFM
|
Australia | AU$164.45K |
Liability Composition Analysis (2014–2024)
This chart breaks down Adbiotech Co. Ltd.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.62 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 15.28 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.00 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Adbiotech Co. Ltd.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Adbiotech Co. Ltd. (2014–2024)
The table below shows the annual total liabilities of Adbiotech Co. Ltd. from 2014 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩18.24 Billion | +5.75% |
| 2023-12-31 | ₩17.25 Billion | +16.27% |
| 2022-12-31 | ₩14.83 Billion | -6.44% |
| 2021-12-31 | ₩15.85 Billion | +66.66% |
| 2020-12-31 | ₩9.51 Billion | +117.47% |
| 2019-12-31 | ₩4.37 Billion | -15.51% |
| 2018-12-31 | ₩5.18 Billion | -11.50% |
| 2017-12-31 | ₩5.85 Billion | -14.17% |
| 2014-12-31 | ₩6.82 Billion | -- |